Company Overview
About Aktis Oncology
Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.
Business Model & Competitive Advantage
The company's lead candidate, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, the same protein that Pfizer's bladder cancer drug Padcev binds to. Aktis's approach uses alpha-emitting isotopes which can hit tumor targets outside the scope of other radiopharmaceuticals. A second candidate, Ac-AKY-2519, targets B7-H3 expressing tumors with an IND filing planned for 2026.
Competitive Landscape 2025–2026
Aktis's IPO ranks as the sector's third-largest since the start of 2024, trailing only offerings from Kyverna Therapeutics and CG Oncology, and its successful debut signals renewed public market interest in companies with differentiated platforms and clear clinical milestones in precision oncology.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Aktis Oncology is an established challenger with significant market presence and competitive offerings in Healthcare & Life Sciences.
Growth Stage
Aktis Oncology has achieved $318M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Aktis Oncology with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Aktis Oncology? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Aktis Oncology Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aktis Oncology vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →